Covered recipient · General Payments record
DIAB MFREJ ALMHANA
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$72,053.39
338 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,090.00 | 26 |
| Travel and Lodging | $5,203.18 | 31 |
| Food and Beverage | $5,149.16 | 278 |
| Consulting Fee | $4,860.00 | 1 |
| Honoraria | $2,750.00 | 1 |
| Education | $1.05 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $31,518.63 | 82 |
| Supernus Pharmaceuticals, Inc. | $25,230.53 | 58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $12,702.21 | 37 |
| Vanda Pharmaceuticals Inc. | $291.99 | 9 |
| Lundbeck LLC | $289.39 | 21 |
| Axsome Therapeutics, Inc. | $269.62 | 18 |
| E.R. Squibb & Sons, L.L.C. | $226.41 | 7 |
| Corium, LLC | $188.61 | 17 |
| Takeda Pharmaceuticals U.S.A., Inc. | $184.68 | 14 |
| IRONSHORE PHARMACEUTICALS INC. | $183.86 | 16 |
| Bausch Health US, LLC | $171.92 | 13 |
| Alkermes, Inc. | $166.71 | 11 |
| Teva Pharmaceuticals USA, Inc. | $138.48 | 8 |
| Otsuka America Pharmaceutical, Inc. | $98.11 | 5 |
| Noven Therapeutics, LLC | $85.99 | 5 |
| Janssen Pharmaceuticals, Inc | $83.02 | 4 |
| Neurocrine Biosciences, Inc. | $70.89 | 4 |
| HARMONY BIOSCIENCES LLC | $46.71 | 3 |
| Sage Therapeutics, Inc. | $42.21 | 2 |
| Tris Pharma Inc | $32.89 | 2 |
| Noven Pharmaceuticals, Inc. | $16.20 | 1 |
| Neos Therapeutics, LP | $14.33 | 1 |
Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DIAB MFREJ ALMHANA
NPI 1619053477 · CMS profile ID 164255
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
AVON LAKE, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619053477?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DIAB MFREJ ALMHANA, NPI 1619053477, CMS profile ID 164255. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619053477?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). DIAB MFREJ ALMHANA, NPI 1619053477, CMS profile ID 164255. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619053477?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- DIAB MFREJ ALMHANA, NPI 1619053477, CMS profile ID 164255, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 338 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1619053477?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
338 matching records · $72,053.39 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 338.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | $34.08 | 09/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133894631 | CMS |
| Otsuka America Pharmaceutical, Inc. | $15.71 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118851600 | CMS |
| Alkermes, Inc. | $13.42 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120456789 | CMS |
| Corium, LLC | $6.67 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100148333 | CMS |
| Supernus Pharmaceuticals, Inc. | $3.91 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860897 | CMS |
| Supernus Pharmaceuticals, Inc. | $12.41 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860905 | CMS |
| Supernus Pharmaceuticals, Inc. | $73.65 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860923 | CMS |
| Supernus Pharmaceuticals, Inc. | $95.80 | 08/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860925 | CMS |
| Supernus Pharmaceuticals, Inc. | $214.33 | 08/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860939 | CMS |
| Supernus Pharmaceuticals, Inc. | $2,000.00 | 08/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860951 | CMS |
| Supernus Pharmaceuticals, Inc. | $2,000.00 | 08/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860953 | CMS |
| Bausch Health US, LLC | $24.42 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148018748 | CMS |
| Supernus Pharmaceuticals, Inc. | $20.30 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860913 | CMS |
| Supernus Pharmaceuticals, Inc. | $25.49 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860919 | CMS |
| Supernus Pharmaceuticals, Inc. | $50.00 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860921 | CMS |
| Supernus Pharmaceuticals, Inc. | $214.31 | 08/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860935 | CMS |
| Supernus Pharmaceuticals, Inc. | $214.31 | 08/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860937 | CMS |
| Supernus Pharmaceuticals, Inc. | $2,000.00 | 08/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860947 | CMS |
| Supernus Pharmaceuticals, Inc. | $2,000.00 | 08/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860949 | CMS |
| Supernus Pharmaceuticals, Inc. | $223.43 | 08/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860955 | CMS |
| Supernus Pharmaceuticals, Inc. | $491.38 | 08/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860957 | CMS |
| Supernus Pharmaceuticals, Inc. | $1,000.00 | 08/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860961 | CMS |
| ABBVIE INC. | $4.22 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103210237 | CMS |
| Teva Pharmaceuticals USA, Inc. | $35.33 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151668901 | CMS |
| Corium, LLC | $21.54 | 08/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100182188 | CMS |
| ABBVIE INC. | $4.29 | 08/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103210235 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,160.00 | 08/14/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143183114 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.83 | 08/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143183118 | CMS |
| Supernus Pharmaceuticals, Inc. | $24.24 | 08/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860917 | CMS |
| Alkermes, Inc. | $14.06 | 08/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120456787 | CMS |
| Lundbeck LLC | $6.59 | 08/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145890911 | CMS |
| Lundbeck LLC | $3.74 | 08/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145890913 | CMS |
| Supernus Pharmaceuticals, Inc. | $147.99 | 08/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860933 | CMS |
| ABBVIE INC. | $6.37 | 08/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103210233 | CMS |
| IRONSHORE PHARMACEUTICALS INC. | $15.68 | 08/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146298376 | CMS |
| Supernus Pharmaceuticals, Inc. | $0.01 | 08/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860891 | CMS |
| Supernus Pharmaceuticals, Inc. | $0.01 | 08/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860893 | CMS |
| Supernus Pharmaceuticals, Inc. | $17.30 | 08/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860911 | CMS |
| Supernus Pharmaceuticals, Inc. | $147.98 | 08/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860927 | CMS |
| Supernus Pharmaceuticals, Inc. | $147.99 | 08/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860929 | CMS |
| Supernus Pharmaceuticals, Inc. | $147.99 | 08/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147860931 | CMS |
| ABBVIE INC. | $4.49 | 08/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103210231 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.33 | 08/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137468877 | CMS |
| Tris Pharma Inc | $14.29 | 08/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147234379 | CMS |
| ABBVIE INC. | $3.88 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103210229 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.93 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143183110 | CMS |
| Alkermes, Inc. | $16.86 | 07/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120456785 | CMS |
| ABBVIE INC. | $13.45 | 07/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103210227 | CMS |
| Neos Therapeutics, LP | $14.33 | 07/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1082672051 | CMS |
| Axsome Therapeutics, Inc. | $25.56 | 07/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148277158 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,312.88 | 9 |
| PY2025 | Principal investigator | $427,508.07 | 81 |
| PY2024 | Principal investigator | $481,234.52 | 54 |
| PY2023 | Principal investigator | $476,495.70 | 64 |
| PY2022 | Principal investigator | $76,290.31 | 27 |
| PY2021 | Principal investigator | $352,859.78 | 33 |
| PY2020 | Recipient | $1,501.41 | 8 |
| PY2020 | Principal investigator | $226,275.36 | 25 |
| PY2019 | Recipient | $957.49 | 6 |
| PY2019 | Principal investigator | $195,107.96 | 12 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
90 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,592.56 | 12/31/2025 | Non-covered Recipient Entity HAIDAR ALMHANA AND NIEDING LLC | Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202533055 |
| Principal investigator 1 | ABBVIE INC. | $3,132.24 | 12/31/2025 | Non-covered Recipient Entity HAIDAR ALMHANA AND NIEDING LLC | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies | No dispute reported | 06/30/2026 | 1202533057 |
| Principal investigator 1 | ABBVIE INC. | $1,558.04 | 12/31/2025 | Non-covered Recipient Entity HAIDAR ALMHANA AND NIEDING LLC | A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1202533059 |
| Principal investigator 1 | ABBVIE INC. | $2,402.52 | 12/31/2025 | Non-covered Recipient Entity HAIDAR ALMHANA AND NIEDING LLC | Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202533061 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,040.62 | 12/22/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-421 | No dispute reported | 06/30/2026 | 1242369433 |
| Recipient | ABBVIE INC. | $707.79 | 12/09/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397110 |
| Recipient | ABBVIE INC. | $60.00 | 12/09/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397114 |
| Recipient | ABBVIE INC. | $24.99 | 12/09/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397118 |
| Recipient | ABBVIE INC. | $70.00 | 12/09/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397122 |
| Recipient | ABBVIE INC. | $84.55 | 12/09/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397125 |
| Recipient | ABBVIE INC. | $235.25 | 12/08/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397095 |
| Recipient | ABBVIE INC. | $29.40 | 12/08/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397098 |
| Recipient | ABBVIE INC. | $50.90 | 12/08/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397103 |
| Recipient | ABBVIE INC. | $50.00 | 12/08/2025 | Covered Recipient Physician | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202397106 |
| Principal investigator 1 | ABBVIE INC. | $21,192.35 | 12/04/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202528352 |
| Principal investigator 1 | ABBVIE INC. | $11,709.30 | 12/04/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202528370 |
| Principal investigator 1 | ABBVIE INC. | $7,226.75 | 12/04/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202528372 |
| Principal investigator 1 | Janssen Research & Development, LLC | $363.00 | 11/17/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms | No dispute reported | 06/30/2026 | 1175332193 |
| Principal investigator 1 | ABBVIE INC. | $4,961.95 | 11/05/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202521593 |
| Principal investigator 1 | ABBVIE INC. | $11,356.20 | 11/05/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202521607 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 11/03/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms | No dispute reported | 06/30/2026 | 1175332185 |
| Principal investigator 1 | ABBVIE INC. | $9,024.75 | 10/09/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202515829 |
| Principal investigator 1 | ABBVIE INC. | $14,500.00 | 10/09/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | A Phase 2, Multicenter, 6-Week, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Icalcaprant in Subjects with Major Depressive Disorder | No dispute reported | 06/30/2026 | 1202515831 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,608.00 | 10/02/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242360038 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $500.00 | 09/24/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-421 | No dispute reported | 06/30/2026 | 1242359558 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $400.00 | 09/22/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242359216 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $3,774.89 | 08/18/2025 | Non-covered Recipient Entity QUEST THERAPEUTICS OF AVON LAKE | ACP-103-070 | No dispute reported | 06/30/2026 | 1245935517 |
| Principal investigator 1 | ABBVIE INC. | $3,600.00 | 07/28/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202500170 |
| Principal investigator 1 | ABBVIE INC. | $1,650.00 | 07/24/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202499556 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,546.00 | 07/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242353819 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,079.00 | 07/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242353821 |
| Principal investigator 1 | ABBVIE INC. | $2,385.45 | 07/02/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202495027 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,134.00 | 06/23/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242351540 |
| Principal investigator 1 | ABBVIE INC. | $580.00 | 06/10/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202490741 |
| Principal investigator 1 | ABBVIE INC. | $33,822.75 | 06/03/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202488943 |
| Principal investigator 1 | ABBVIE INC. | $1,425.60 | 06/03/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder | No dispute reported | 06/30/2026 | 1202488945 |
| Principal investigator 1 | ABBVIE INC. | $9,472.00 | 05/22/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1202485769 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $754.00 | 05/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242348242 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,220.00 | 05/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242348284 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,846.00 | 05/19/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-505 | No dispute reported | 06/30/2026 | 1242347576 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,106.00 | 05/19/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-505 | No dispute reported | 06/30/2026 | 1242347578 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,100.00 | 05/19/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-505 | No dispute reported | 06/30/2026 | 1242347580 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $3,200.00 | 05/12/2025 | Non-covered Recipient Entity QUEST THERAPEUTICS OF AVON LAKE | ACP-103-070 | No dispute reported | 06/30/2026 | 1245934213 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $125.78 | 05/12/2025 | Non-covered Recipient Entity QUEST THERAPEUTICS OF AVON LAKE | ACP-103-069 | No dispute reported | 06/30/2026 | 1245934215 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $800.00 | 05/09/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242347338 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,000.00 | 05/09/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242347340 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $850.00 | 05/09/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242347342 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6,000.00 | 05/09/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242347344 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $9,500.00 | 05/09/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242347346 |
| Principal investigator 1 | ABBVIE INC. | $30,152.10 | 05/07/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202482581 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 05/07/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder | No dispute reported | 06/30/2026 | 1202482583 |
| Principal investigator 1 | ABBVIE INC. | $14,500.00 | 05/07/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202482585 |
| Principal investigator 1 | ABBVIE INC. | $4,295.25 | 05/06/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder | No dispute reported | 06/30/2026 | 1202481317 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,157.00 | 04/23/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242343971 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,054.00 | 04/23/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242343973 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.00 | 04/23/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242343975 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $87.00 | 04/23/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242343977 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.00 | 04/23/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242343979 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $5,775.72 | 04/10/2025 | Non-covered Recipient Entity QUEST THERAPEUTICS OF AVON LAKE | ACP-103-069 | No dispute reported | 06/30/2026 | 1245934045 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $178.00 | 04/09/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242340834 |
| Principal investigator 1 | ABBVIE INC. | $3,565.00 | 04/08/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202474977 |
| Principal investigator 1 | ABBVIE INC. | $1,849.50 | 04/03/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder | No dispute reported | 06/30/2026 | 1202471875 |
| Principal investigator 1 | ABBVIE INC. | $27,717.30 | 04/03/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202472233 |
| Principal investigator 1 | ABBVIE INC. | $14,500.00 | 04/03/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202472236 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,220.00 | 04/02/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242339071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,050.00 | 03/24/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso | No dispute reported | 06/30/2026 | 1175332199 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,862.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338625 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,306.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338627 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,128.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338629 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,128.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338631 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,794.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338633 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,128.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338635 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,128.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338639 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $74.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338641 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.00 | 03/21/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-602 | No dispute reported | 06/30/2026 | 1242338643 |
| Principal investigator 1 | ABBVIE INC. | $9,897.00 | 03/07/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202461796 |
| Principal investigator 1 | ABBVIE INC. | $3,275.10 | 03/06/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder | No dispute reported | 06/30/2026 | 1202458584 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,134.00 | 02/25/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242333024 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,608.00 | 02/25/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242333026 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $5,338.00 | 02/25/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-421 | No dispute reported | 06/30/2026 | 1242333238 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,617.00 | 02/25/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-421 | No dispute reported | 06/30/2026 | 1242333240 |
| Principal investigator 1 | ABBVIE INC. | $338.85 | 02/06/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202449120 |
| Principal investigator 1 | ABBVIE INC. | $8,122.50 | 02/05/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder | No dispute reported | 06/30/2026 | 1202445539 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,499.00 | 02/05/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242329977 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,608.00 | 02/05/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242329985 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $2,940.00 | 02/05/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-321 | No dispute reported | 06/30/2026 | 1242329987 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,709.00 | 01/13/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-421 | No dispute reported | 06/30/2026 | 1242328639 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,044.00 | 01/13/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-421 | No dispute reported | 06/30/2026 | 1242328641 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $3,044.00 | 01/13/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-421 | No dispute reported | 06/30/2026 | 1242328643 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,970.00 | 01/13/2025 | Non-covered Recipient Entity HAIDAR ALMHANA NIEDING LLC | ITI-007-421 | No dispute reported | 06/30/2026 | 1242328645 |